Monika Wujec

Prof. Monika Wujec

Medical University of Lublin, Lublin, Lubelskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TPTomasz Plech
Tomasz Plech
Monika WujecMonika Wujec
Monika Wujec
ASAgata Siwek
Agata Siwek
UKUrszula Kosikowska
Urszula Kosikowska
Anna MalmAnna Malm
Anna Malm

1 February 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TPTomasz Plech
Tomasz Plech
Monika WujecMonika Wujec
Monika Wujec
UKUrszula Kosikowska
Urszula Kosikowska
Anna MalmAnna Malm
Anna Malm
BRBarbara Rajtar
Barbara Rajtar
Małgorzata Polz-DacewiczMałgorzata Polz-Dacewicz
Małgorzata Polz-Dacewicz

20 September 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Sara JanowskaSara Janowska
Sara Janowska
APAgata Paneth
Agata Paneth
Monika WujecMonika Wujec
Monika Wujec
During recent years, small molecules containing five-member heterocyclic moieties have become the subject of considerable growing interest for designing new antitumor agents. One of them is 1,3,4-thiadiazole. This study is an attempt to collect the 1,3,4-thiadiazole and its derivatives, which can be considered as potential anticancer agents, reported in the literature in the last ten years.

1 February 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TPTomasz Plech
Tomasz Plech
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
Monika WujecMonika Wujec
Monika Wujec
JFJolanta Flieger
Jolanta Flieger
MPMagdalena Pizoń
Magdalena Pizoń

10 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Sara JanowskaSara Janowska
Sara Janowska
Dmytro KhylyukDmytro Khylyuk
Dmytro Khylyuk
ABAnna Bielawska
Anna Bielawska
ASAnna Szymanowska
Anna Szymanowska
AGAgnieszka Gornowicz
Agnieszka Gornowicz
Monika WujecMonika Wujec
Monika Wujec
We designed and synthesized the 1,3,4-thiadiazole derivatives differing in the structure of the substituents in C2 and C5 positions. The cytotoxic activity of the obtained compounds was then determined in biological studies using MCF-7 and MDA-MB-231 breast cancer cells and normal cell line (fibroblasts). The results showed that in both breast cancer cell lines, the strongest anti-proliferative activity was exerted by 2-(2-trifluorometylophenylamino)-5-(3-methoxyphenyl)-1,3,4-thiadiazole. The IC50 values of this compound against MCF-7 and MDA-MB-231 breast cancer cells were 49.6 µM and 53.4 µM, respectively. Importantly, all new compounds had weaker cytotoxic activity on normal cell line than on breast cancer cell lines. In silico studies demonstrated a possible multitarget mode of action for the synthesized compounds. The most likely mechanism of action for the new compounds is connected with the activities of Caspase 3 and Caspase 8 and activation of BAX proteins.

1 July 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
ŁPŁukasz Popiołek
Łukasz Popiołek
IPIwona Piątkowska-Chmiel
Iwona Piątkowska-Chmiel
MGMonika Gawronska-Grzywacz
Monika Gawronska-Grzywacz
ABAnna Biernasiuk
Anna Biernasiuk
MIMagdalena Izdebska
Magdalena Izdebska
Monika WujecMonika Wujec
Monika Wujec